Sanofi India Limited

Sanofi India's strong Q3 FY26 performance, highlighted by a 54% jump in profit after tax to ₹1,167 crore, underscores the resilience of its core diabetes portfolio and effective cost management. The company's board approved an interim dividend of ₹75 per share, reflecting robust financial health and commitment to shareholder returns. Concurrent with these results, a significant inter-se transfer of shares occurred within the promoter group, with Sanofi Healthcare India acquiring a 15.20% stake from Hoechst GmbH, resulting in a shift in ownership while maintaining overall promoter control. These developments suggest continued operational strength and strategic adjustments within the company's ownership structure, potentially positioning Sanofi India favorably for future growth.